Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement.
Frontiers in immunology（2023）
摘要
Clinicaltrials.gov, NCT04835870.
更多查看译文
关键词
zanubrutinib, untreated non-GCB DLBCL, extranodal involvement, anti-tumor activity, oncogenic mutations
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要